Contact information Verified work emails, personal emails, and direct dials — unlocked in one click.
Work email
g••••••••@syncromune.com
Personal email
•••••@•••••.com
Free to start · No credit card required
Current company Syncromune®
Biotechnology Research · 58 employees · Founded 2020 · Fort Lauderdale, Florida, United States
LEGION-100 Trial for Metastatic Prostate Cancer is Now Enrolling - Learn More: www.legion100trial.com
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, a potentially first-in-class cancer immunotherapy platform designed to address major unmet needs and treatment challenges of incurable metastatic solid tumors. SYNC-T is an in situ personalized cancer therapy engineered to synchronize the location of three components critical to T cell activation and an anti-tumor immune response: tumor antigens, immune cells, and our multi-target biologic drug. SYNC-T features a novel proprietary device delivery system that is optimized for combination drug/device immunotherapy. First, the system lyses a portion of a target tumor to rupture tumor cells and release a heterogeneous population of tumor antigens into the tumor microenvironment (TME) that may help the immune system recognize cancer. Next, the delivery system facilitates the infusion of our proprietary multi-target immunomodulatory drug directly into the tumor in the zone that was lysed. The volume of the infusion promotes flow of the tumor antigens and drug into tumor-draining lymph nodes where they synchronize location with immune cells, aiming to create conditions for T cell activation. The combination therapy targets numerous mechanisms of cancer, promoting in situ immune activation while also battling immune suppression and minimizing systemic drug exposure. The goal is to empower the immune system to recognize and attack both the primary cancer and metastatic lesions throughout the body and defend with immune memory. Our investigational lead candidate, SYNC-T Therapy SV-102 is being evaluated for metastatic castration-resistant prostate cancer (mCRPC), in LEGION-100, a U.S., multicenter, Phase 2 trial. For more information, please visit www.legion100trial.com.